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Basal gangliaThe dopaminergic neurons of the basal ganglia play critical roles in CNS function and human disease, but
speciﬁcation of dopamine neuron phenotype is poorly understood in vertebrates. We performed an in vivo
screen in zebraﬁsh to identify dopaminergic neuron enhancers, in order to facilitate studies on the
speciﬁcation of neuronal identity, connectivity, and function in the basal ganglia. Based primarily on
identiﬁcation of conserved non-coding elements, we tested 54 DNA elements from four species (zebraﬁsh,
pufferﬁsh, mouse, and rat), that included 21 genes with known or putative roles in dopaminergic neuron
speciﬁcation or function. Most elements failed to drive CNS expression or did not express speciﬁcally in
dopaminergic neurons. However, we did isolate a discrete enhancer from the otpb gene that drove speciﬁc
expression in diencephalic dopaminergic neurons, although it did not share sequence conservation with
regulatory regions of otpa or other dopamine-speciﬁc genes. For the otpb enhancer, regulation of expression in
dopamine neurons requires multiple elements spread across a large genomic area. In addition, we compared
our in vivo testing with in silico analysis of genomic regions for genes involved in dopamine neuron function,
but failed to ﬁnd conserved regions that functioned as enhancers. We conclude that regulation of
dopaminergic neuron phenotype in vertebrates is regulated by dispersed regulatory elements.Utah, 20 North 1900 East, Salt
. Bonkowsky).
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
The basal ganglia and their dopaminergic neurons play critical
roles in CNS function with vital roles in initiation and regulation of
movement, limbic emotional responses, and reward-mediated
aspects of behavior and learning. Several human diseases including
Parkinson's disease, attention-deﬁcit hyperactivity disorder, Tour-
ette's syndrome, and addiction behaviors have been linked with
pathology of basal ganglia dopaminergic neurons (Nussbaum and
Ellis, 2003; Albin and Mink, 2006; Hyman et al., 2006). In mammals,
groups of dopaminergic neurons are located in discrete nuclei in the
telencephalon, diencephalon, and mesencephalon. The mesodience-
phalic dopaminergic (mesDA) neurons constitute the largest fraction
of dopaminergic neurons in the brain (roughly 75%; Wallén and
Perlmann, 2003) and include three distinct sets of nuclei (Dahlstroem
and Fuxe, 1964): the substantia nigra pars compacta (group A9), the
retrorubral ﬁeld (group A8), and the ventral tegmental area (group
A10).
The mesDA system is highly complex both in its organization and
function. Its neurons integrate pathways of information from the
striatum and cortex in which there is somatotopic representation ofdistinct body parts, and also sorting of parallel functional pathways for
different cortical modalities (such as limbic behaviors or motor
function; DeLong andWichmann, 2009). Accordingly, mesDA neurons
are heterogeneous with respect to their development (Smidt et al.,
2000), projections, intrinsic electrophysiologic properties (Lammel
et al., 2008), and neurotransmitter identities.
Speciﬁcation of mesDA neurons is controlled by a developmental
cascade of transcription factors (Abeliovich andHammond, 2007; Smidt
and Burbach, 2007). However, it is not knownwhether this hierarchical
cascade alone is sufﬁcient to specify mesDA neuron identity (including
neurotransmitter status and axon projections), or whether additional
information is necessary to providemore precise identities for subtypes
of mesDA neurons. For example, the orphan nuclear receptor nurr1 is
necessary for generation and maintenance of mesDA neurons, as
assayed by absent tyrosine hydroxylase (TH) expression in knock-out
mice (Zetterström et al., 1997; Saucedo-Cardenas et al., 1998; Wallén
et al., 1999). However, in nurr1 knock-out mice, some neurons destined
to express TH still differentiate partially; nigrostriatal projections still
develop normally; and the neurons express other markers (such as
cholecystokinin) speciﬁc to dopaminergic neurons (Witta et al., 2000).
nurr1 is only partially responsible for specifying dopamine neuron-
speciﬁc gene expression: while vmat2 and dat require nurr1, aadc
expression is induced independently (Smits et al., 2003). Therefore,
while nurr1 is necessary for terminal differentiation of mesDA
neurons including the expression of several dopamine-neuron speciﬁc
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elements of mesDA identity such as axon pathﬁnding, and does not
appear to affect development of other dopaminergic neuron groups in
the CNS (Baekman et al., 1999).
Another key unanswered question is how the genes necessary for
dopaminergic neuron function are regulated. Multiple genes neces-
sary for dopamine neuron function, survival, and axon pathﬁnding
must be coordinately expressed in the correct subset of neurons.
Elegant work from C. elegans has shown that a single cis-regulatory
element and associated transcription factor (Ast-1) are necessary and
sufﬁcient for establishing dopamine neuron neurotransmitter identity
(Flames and Hobert, 2009). Whether such a system is present in
vertebrates is unknown. Because of the complexity of dopaminergic
neuron development, as well as the involvement of the mesDA
neurons in disease processes, identifying a discrete enhancer element
speciﬁc for mesDA neurons would facilitate studies on the speciﬁca-
tion of neuronal identity and function in the basal ganglia.
In the present study we have performed an in vivo screen in
zebraﬁsh to identify dopaminergic neuron-speciﬁc enhancers. In
zebraﬁsh, dopaminergic neurons are present in the diencephalon but
not the mesencephalon (Holzschuh et al., 2001; Kastenhuber et al.,
2010), with projections in the adult to the subpallium (striatum) (JLB,
unpublished data; Rink and Wullimann, 2001, 2002; Kastenhuber
et al., 2010). Furthermore, chemical ablation of the diencephalic
dopaminergic (diDA) neurons phenotypically mimics loss of mesDA
neurons in mammals (Lam et al., 2005; McKinley et al., 2005; Wen
et al., 2008). We have identiﬁed a minimal 4.5 kb enhancer element
associated with the otpb gene that is sufﬁcient to drive expression in
speciﬁc dopaminergic neurons of the diencephalon in zebraﬁsh.
However, this enhancer (otpb.A) only drives expression in a subset of
CNS dopaminergic neurons, and analysis of other dopaminergic-
speciﬁc gene regions failed to identify a discrete enhancer with
function in CNS neurons. Furthermore, we were unable to detect any
conservation between the sequence of the otpb.A enhancer element
and the roughly 50 kb genomic neighborhoods (the most likely
location of regulatory regions) of other genes speciﬁc to dopaminergic
neurons. Our analysis of zebraﬁsh dopaminergic gene regulatory
regions reveals that conserved DNA elements are widely dispersed
over large genomic loci.
Materials and methods
Fish stocks and embryo raising
Adult ﬁsh were bred according to standard methods. Embryos
were raised at 28.5 °C in E3 embryo medium and staged by time and
morphology (Kimmel et al., 1995). For in situ staining, embryos were
ﬁxed in 4% paraformaldehyde (PFA) in PBS for 3 h at room
temperature (RT) or overnight (O/N) at 4 °C, washed brieﬂy in PBS,
dehydrated, and stored in 100% MeOH at −20 °C until use.
Transgenic ﬁsh lines and alleles used in this paper were the
following: Tg(otpb.A:egfp)zc48 (ofﬁcial ZFIN nomenclature Tg(otpb:
EGFP)zc48), Tg(fezf2:egfp)zc55, Tg(pitx3:egfp)zc50, Tg(f.TH.A:egfp)zc56, Tg
(otpb.A:GAL4)zc57 (ofﬁcial ZFIN nomenclature Tg(otpb:Gal4-VP16)zc57),
Tg(otpb.I:GAL4)zc66, and Tg(UAS:GFP) [Tg(5xUAS:GFP)nkuasgfp1a—kind
gift of K. Kawakami]. Lines are available upon request.
Immunohistochemistry and in situ hybridization
Following ﬁxation and dehydration in methanol, embryos were
rehydrated, permeabilized using proteinase K [10 μg/mL in PBST (PBS
with 0.1% Tween-20)] at 28 °C for 60′ (8′ for 24 hpf; 20′ for 36 hpf;
and 30′ for 48 hpf) without rocking, washed twice in PBST for 5′ then
re-ﬁxed for 15′. Embryos were then washed in PBST, blocked in PBST/
1% DMSO/2% BSA/5% normal goat serum (NGS), and then incubated O/
N in a primary antibody solution diluted in PBST/1% DMSO/2% BSA/2%NGS at 4 °C. The next day embryos were washed in PBST/1% DMSO/1%
NGS for aminimum of 6 h, followed by incubation O/Nwith secondary
antibodies, and washing the following day. Antibodies and concen-
trations used were rabbit polyclonal anti-tyrosine hydroxylase 1:400
(Millipore), mouse monoclonal anti-GFP 1:400 (Millipore), Cy-3 anti-
rabbit 1:400, and Alexa 488 anti-mouse 1:400.
Double immunohistochemistry/in situ labeling was performed by
permeabilization using 0.1% collagenase in PBST, re-ﬁxation for 10′
with 4% PFA, and then performing anti-GFP antibody staining and
detection in PBST using rabbit polyclonal anti-GFP 1:400 (Millipore
#11122) followed by anti-rabbit Alexa 488 1:250 (Invitrogen).
Following washing in PBST, embryos were ﬁxed for 1 h, washed
with PBST, then re-permeabilized using 0.1% collagenase at RT.
Whole-mount in situ labeling for dat (Holzschuh et al., 2001) and
isotocin (Blechman et al., 2007) was then performed, followed by
plastic sectioning, as previously described (Bonkowsky and Chien,
2005).
Genomic PCR and enhancer cloning
PCR primers used to clone genomic fragments are listed in
Table S1. PCR and cloning of genomic fragments into pDONR P4-P1R
were performed as described (Bonkowsky et al., 2008). The identity of
the genomic fragments was conﬁrmed by restriction enzyme digests
and partial sequencing. Unless otherwise speciﬁed, the minimal
promoter used for expression in Gateway constructs was the
adenovirus E1b TATA box with the carp β-actin 5′-UTR fragment
(Kwan et al., 2007; Bonkowsky et al., 2008). Speciﬁc plasmids used for
cloning were pME-basEGFP (middle entry clone with EGFP preceded
by minimal promoter), pDestTol2pA2, pDestTol2CG2, and pDest-
Tol2CR3 (pDestTol2pA3 with cmlc2:TagRFP transgenesis marker);
pME-basGal4-VP16413–470 (Koester and Fraser, 2001; Ogura et al.,
2009) was used for generation of GAL4 transgenic lines. pME-
gata2EGFP is a middle entry clone with EGFP proceeded by the
gata2aminimal promoter (Meng et al., 1997; Bessa et al., 2009). pME-
cfosEGFP is a middle entry clone with EGFP preceded by the mouse c-
fos minimal promoter (Dorsky et al., 2002).
Injection of DNA constructs and raising of stable transgenic lines
were performed essentially as described (Fisher et al., 2006; Kwan
et al., 2007; Bonkowsky et al., 2008). Patterns of enhancer expression
were conﬁrmed by transient injections of each construct (N100
embryos per construct), as well as isolation of two or more
independent stable transgenic lines (in cases where stable transgenics
were isolated). Plasmids and speciﬁc PCR conditions are available
upon request.
Microscopy and image analysis
Image acquisition and analysis were performed essentially as
described previously (Suli et al., 2006). Images of embryos processed
for immunohistochemistry were taken using a confocal microscope;
embryos were taken step-wise into a solution of 80% glycerol/20%
PBST, then mounted on a glass slide with a #0 coverslip ﬁxed into
place over a well made using electrical tape. NIH ImageJ software (W.
Rasband, NIMH) was used to merge slices to create maximal intensity
z-stack projections.
Comparative genomic analysis
Cross-species non-coding conservation was determined by exam-
ination of the zebraﬁsh genome assembly Zv5 at the UCSC genome
browser (http://genome.ucsc.edu/) (Siepel et al., 2005). The “DA
motif” was deﬁned using the position weight matrix scoring from
Flames and Hobert (2009). Sequence comparisons for DA motifs and
cross-gene comparisons were done using sequence from Zv7. DA
motif searches of DNA fragments were performed using ConSite
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2004). Genomic DNA comparisons between non-coding regions of
genes were performed using Shufﬂe-LAGAN in rVISTA (Brudno et al.,
2003; Frazer et al., 2004). Genomic regions chosen for comparison
were centered on each coding regions, encompassing 86.5 kb from the
ddc locus, 51.3 kb from the slc6a3 locus, 76.1 kb from the th1 locus,
and 42.2 kb from the slc18a2 locus. Shared synteny was determined
from genetic maps from the Ensembl and UCSC genome browsers
(Hubbard et al., 2009; Rhead et al., 2010).
Results
Screen for dopaminergic neuron enhancers
We undertook a screen to identify genomic DNA fragments which
might serve as enhancers to drive expression in dopaminergic
neurons of the zebraﬁsh brain, with minimal expression in other
neuron types. The identiﬁcation of potential enhancer fragments was
based on the concept of conserved non-coding sequence serving as
potential enhancers (Allende et al., 2006; Gómez-Skarmeta et al.,
2006; Pennacchio et al., 2006). This assumes that regions of
nucleotide conservation (usually of greater than 60–70% identity)
between species in regions of conserved syntenic blocks of genes may
function as enhancers (or silencers) of transcription.
We cloned genomic fragments using PCR into a Tol2 transposon-
based vector (Kawakami, 2004; Kwan et al., 2007; Villefranc et al.,
2007). Genomic DNA fragments were chosen based on their location
in relative proximity to a target gene (described below), location
upstream of the ﬁrst coding exon (for some targets), and conservation
of non-coding sequence (using the UCSC genomeweb browser http://
genome.ucsc.edu/) (Kent et al., 2002; Bejerano et al., 2005). To
visualize expression driven by the potential enhancers, the DNA
fragments were cloned immediately upstream of a minimal promoter
followed by GFP (Kwan et al., 2007; Villefranc et al., 2007). We have
previously demonstrated that this minimal promoter is competent to
drive expression in diverse CNS cell types without ectopic expression
(Bonkowsky et al., 2008). We also tested the gata2a and c-fosminimal
promoters using previously characterized enhancers (Dorsky et al.,
2002; Bessa et al., 2009), but found higher rates of ectopic expression
in non-target tissues (JLB, unpublished data). To test for expression,
we injected one-cell stage embryos and looked for GFP expression
from 12 hpf through 96 hpf. The ﬁrst expression of th in zebraﬁsh is
between 16 and 20 hpf (Holzschuh et al., 2001). Transient expression
was analyzed in 100–200 embryos; if we observed consistent CNS
expression in a region that potentially had overlapwith diDA neurons,
we raised stable transgenic lines for characterization. Characterization
of stable transgenic lines consisted of double immunohistochemistry
for GFP and for tyrosine hydroxylase (TH).
We used a comprehensive strategy to identify potential target
genes, choosing them from two classes (Table 1). The ﬁrst class were
genes with known or putative roles in dopaminergic neuron
speciﬁcation [including FEZ family zinc ﬁnger 2 (fezf2), LIM homeobox
transcription factor 1 alpha 2 (lmx1a.2), muscle segment homeobox E
(msxE), neurogenin 1 (ngn1), nuclear receptor subfamily 4 group A
member 2a (nr4a2a, a homolog of mammalian nurr1), orthopedia
homolog a and b (otpa and otpb), and paired-like homeodomain
transcription factor 3 (pitx3)] (Abeliovich and Hammond, 2007; Smidt
and Burbach, 2007). The second class were genes with roles in
dopaminergic neuron function: aromatic acid decarboxylase (ddc,
previously known as aadc), dopamine receptor (drd2b), tyrosine
hydroxylase (th, to be distinguished from its paralog th2), dopamine
transporter (slc6a3, previously dat), and vesicular monoamine trans-
porter 2 (slc18a2, previously vmat2). In some cases we tested for
overlap of expression of a particular gene with th by double-labeling
for its mRNA by in situ hybridization, and TH by immunohistochem-
istry (data not shown). In addition to analyzing zebraﬁsh genomicfragments for potential dopaminergic enhancer activity, we also
tested elements from pufferﬁsh, mouse, and rat. Genomic DNA
fragments were also cloned from pufferﬁsh (Fugu rubripes) because
of its compact genome size and the assumption that intergenic
regions would be enriched for sequences that could serve as
enhancers (Brenner et al., 1994). Enhancers from mouse and rat
were chosen because of their known expression in dopaminergic
neurons (such as the rat TH promoter) (Schimmel et al., 1999), or
expression in the mesodiencephalon (VISTA Enhancer Browser—Visel
et al., 2007). Finally, we tested a BAC with GFP inserted at the mouse
slc6a3 region (GENSAT1—BX1837) (Gong et al., 2003).
We tested 54 fragments from 21 different genes. In many cases no
CNS expressionwas seen.We found that DNA fragments isolated from
regions near genes encoding transcription factors were more likely to
function in vivo as enhancers, a phenomenon that has also been noted
for other tissue types (Sandelin et al., 2004; Woolfe et al., 2005). For
fragments that functioned as CNS enhancers during development,
most showed either minimal or no overlap with TH-positive neurons
(as for Tg(fezf2:egfp)zc55 and msxE:EGFP, Figs. 1A–C and Figs. S2E–G)
or had widespread expression in non-TH neurons (Tg(pitx3:egfp)zc50,
Tg(f.TH.A:egfp)zc56, and Tg(lmx1a.2:egfp)) (Figs. 1D–E and Figs. S2A–D).
pitx3 has subsequently been shown not to express in dopaminergic
neurons in zebraﬁsh (Filippi et al., 2007). Expression patterns from the
transgenic lines Tg(lmx1a.2:egfp), Tg(fezf2:egfp)zc55 and Tg(pitx3:egfp)zc50
appear tomatchwith theknownexpressiondomains of lmx1a.2, fezf2 and
pitx3, respectively (Fig. S2; Blechman et al., 2007; Filippi et al., 2007),
indicating that our enhancer lines recapitulate endogenous gene
expression at least to some extent.
Since it is possible that some enhancers failed to function in vivo
because theymight require a speciﬁc promoter (Gehrig et al., 2009), we
also tested two of our genomic DNA fragments with two additional
alternate promoters (gata2a and c-fos). We tested a fragment from the
ddc gene, and the optb.A enhancer (described further below). The ddc
fragmentdid not drive expressionwith any of the threepromoters (data
not shown). Expression driven by the otpb.A enhancer in transient
injections was similar with all three promoters (Supplemental Fig. S1),
although more ectopic non-CNS expression (compared to the stable
transgenic otpb.A lineand theendogenousotpbexpressionpattern)was
seen using the c-fos and gata2aminimal promoters. Another possibility
is that a gene's endogenous promotermight be necessary for enhancer-
driven expression. However, we tested the known endogenous
promoter for slc6a3 in one of our constructs, and for many other tested
fragments, their size and location immediately upstream of the
translation start site make it very likely that they include the
endogenous promoter (including fragments for the genes th, drd2b,
Fugu dat, otpa, Fugu otpb, and slc18a2).
We characterized most enhancers that had CNS expression by
generation of a stable transgenic line, and have maintained some of
these lines (Table 1). The failure of some DNA fragments to function as
enhancers despite high cross-species non-coding conservation might
be due to function as a repressor or silencer of expression; to the
fragment regulating expression at a different (non-embryonic) stage;
or to insufﬁciency of the element in isolation to drive expression.
Analysis of genomic regions of dopaminergic neuron phenotype genes
Because of our difﬁculty in identifying a discrete enhancer with
expression speciﬁc to dopaminergic neurons (with one exception, see
below), we sought to address how dopaminergic neuron phenotype is
regulated in vertebrates. To addresswhether vertebrate dopaminergic
neuron phenotype requires a single, discrete cis-regulatory element,
or a dispersed complex code of binding sites, we examined a core
group of genes whose expression is relatively speciﬁc to dopamine
neurons, using both in silico and in vivo approaches. For our core group
of dopaminergic phenotype genes we chose genes expressed by all
neurons that use dopamine as a neurotransmitter, including the rate-
Table 1
Table of genomic DNA fragments tested in vivo, grouped according to functional category, gene, and species. Position relative to translation start site (chosen instead of
transcriptional start site because of variability in zebraﬁsh genome annotation), and enhancer fragment size are also listed. Primer sequences are in Table S1.
Gene Enhancer Species Categorya CNS expressionb Stable/allelec Positiond (kb) Fragment size (kb)
ddc Dr F − 6.6 3.4
slc6a3 A Dr F − −0.7 1.9
E Dr F − −5.1 5.1
slc6a3 (BAC) BX1837e Mm F −
drd2B A Dr F − −0.2 6.7
f.slc6a3 A Fr F − −0.4 4.5
B Fr F − 1.7 3.8
fezl Dr T + −3.4 3.7
LBf 219 Mm − FOXP2 intragenic 1.3
298 Mm + SHFM1-DLX5 0.7
304 Mm + JMJD2C-PTPRD 0.6
Lmx1a.2 A Dr T + + −0.1 5.2
B Dr T + + −2.0 1.3
C Dr T + + −0.1 2.5
msxE Dr T + + −0.1 2
ngn1g 3.1delLATE Dr T + + 0 2.4
nurr1 Dr T − 4.5 4.5
otpa Dr T − 1.0 2.4
f.otpb A Fr T − −0.1 2.0
B Fr T − −2.1 1.8
otpb A Dr T + +; zc48 −4.8 4.4
B Dr T − + −4.8 1.8
C Dr T + + −4.1 3.7
D Dr T − + −7.2 2.5
E Dr T + + −4.1 2.7
F Dr T − −1.3 1.3
G Dr T + −4.8 3.4
H Dr T − −4.1 1.1
I Dr T + −2.8 0.4
pitx3 A Dr T + +; zc50 −0.3 6.7
f.TH A Fr F + +; zc56 −5.4 5.1
B Fr F + + −2.7 2.7
C Fr F − − −5.4 3.1
D Fr F − − −8.0 2.7
E Fr F + + −2.6 0.8
F Fr F − − −1.1 1.3
G Fr F + + −7.7 7.8
H Fr F − − −6.1 6.0
I Fr F − − −6.1 3.5
J Fr F − − −2.6 0.3
K Fr F + + −2.3 0.5
L Fr F + + −2.2 0.4
M Fr F + + −2.3 0.3
O Fr F − − −1.8 0.7
rat THh Rn F − −0.1 4.5
th A Dr F − −12 2.3
B Dr F − −4.7 4.5
C Dr F − −2.1 5.8
D Dr F − 7.3 6
uchL1 A Dr F − −0.8 1.1
slc18a2 A Dr F − 0.1 0.3
B Dr F − −3.1 1
C Dr F − −10.6 1
D Dr F − 0.1 2
Abbreviations: LB: Lawrence-Berkeley clones; Fr: Fugu rubripes (pufferﬁsh); Mm: Mus musculus (mouse); Rn: Rattus norvegicus (rat); Dr: Danio rerio (zebraﬁsh).
a “Category” refers to the gene type- F: functional (function of dopamine neurons), T: transcription factor involved in specifying dopamine neurons.
b Expression was evaluated from 12 hpf through 96 hpf.
c Stable indicates that a stable transgenic line was generated and tested. If the line has been maintained this is indicated by an allele number.
d “Position” is relative to translation start site (negative is upstream); except for Lawrence-Berkeley clones, which lists ﬂanking or intragenic region.
e GENSAT1 BAC clones (Gong et al., 2003).
f Visel et al. (2007).
g Blader et al. (2004).
h Schimmel et al. (1999).
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L-dopa to dopamine ddc, the pre-synaptic uptake receptor slc6a3, and
the cytosol to synaptic vesicle transporter slc18a2.
First, we examined whether the genomic neighbors for the
dopaminergic phenotype genes are conserved across evolutionary
time. For vertebrate genes, conserved synteny of genes in “genomic
regulatory blocks” is associated with dispersal of cis-regulatory
elements among the coding exons of the different genes (reviewedin Kikuta et al., 2007). We compared conserved synteny between
human, mouse, zebraﬁsh, and pufferﬁsh regions for the genes ddc,
slc6a3, th, and slc18a2 (Fig. 2A). In all cases, there was at least partial
conservation of synteny between zebraﬁsh and other vertebrates,
suggesting that necessary cis-regulatory elements may be present in
these regions.
Next, we looked for conserved cross-species conservation in
genomic regions surrounding DA neuron-speciﬁc genes, and tested in
Fig. 1. Examples of stable transgenic enhancer lines generated; ventral views, anterior to the top, double-immunohistochemistry for GFP and TH (green and red), confocal z-stacks.
Scale bars are 50 μm. (A–C) Time-series of Tg(fezf2:egfp)zc55 expression at 24 hpf, 48 hpf, and 72 hpf, shows non-overlap of TH andGFP expression. (D–D″) Tg(pitx3:egfp)zc50 and (E–E″) Tg
(f.TH.A:egfp)zc56 at 72 hpf, showspartial overlap of enhancer expression andTH(arrows), but alsowide spreadexpressionof theenhancer innon-THneurons (arrowheads). Insets inD′ and
E′ show single confocal plane of double-labeling, emphasizing the minimal overlap of TH and GFP labeling.
397E. Fujimoto et al. / Developmental Biology 352 (2011) 393–404vivo the ability of different genomic fragments to act as enhancers.
Surprisingly, none of the genomic fragments we tested in vivo drove
expression in DA neurons, or even in the CNS (Table 1; Fig. 2B).
Furthermore, this was despite the presence inmany of the fragments of
multiple copies of the “DAmotif” (Flames and Hobert, 2009), as well as
high cross-species conservation in some fragments. We found that the
presence of the DA motif was no more frequent (and with no higher
matrix scores) than in a CNS enhancer not expressed in DA neurons
(foxP2-enhancerA, Bonkowsky et al., 2008). We also constructed and
tested a DA motif (5′-gcagaggaggaagagtggaga-3″) triplet multimer,
fused to a basal promoter and GFP, but did not ﬁnd speciﬁc CNS
expression. A separate study has also tried to identify a DA-speciﬁc
enhancer from the slc6a3 region, and tested an 11-kb fragment
encompassing the transcription start and regions upstream (Bai and
Burton, 2009). This 11-kb enhancer drove expression in dopaminergic
neurons of thepre-tectal region, but not in other dopaminergic neurons,
and also had ectopic expression in many CNS cell groups, implying the
absence of both necessary enhancer elements as well as of silencing
elements. Together, these results show that in vertebrates a single
discrete DA motif is not sufﬁcient for expression in DA neurons.
We also performed a detailed expression analysis of potential
enhancers from the Fugu th genomic region (Fig. S3). The originaltransgenic line Tg(f.TH.A:egfp)zc56 showed expression in most diDA
neurons (Fig. 1), but also had expression in many non-DA neurons.
Although we tested a large number of fragments and transgenic lines
based on this original enhancer (Fig. S3), none gave speciﬁc expression
in DA neurons alone.
Whilewe did notﬁnd that theDAmotifwas sufﬁcient for expression
in dopaminergic neurons, an alternative explanation is that a different
conserved element is used in vertebrates. To try to identify whether
there were other elements in the loci of the dopamine phenotype genes
that might specify for DA neuron expression, we did a comparative
analysis of the zebraﬁsh genomic loci for th, ddc, slc6a3, and slc18a2, to
identify highly conserved (N70%) regions of 50 bp or more. We found
42, 53, and 65 regions in the th locus that were highly conserved with
regions in the slc6a3, slc18a2, and ddc loci, respectively; and only 1
region thatwas conserved in all 4 genomic loci (Fig. 2B). These regions of
conservation were dispersed over the entirety of each genomic locus.
Furthermore, our previous in vivo analysis had tested some of these
regions which failed to drive CNS expression. Similarly, genomic
fragments for the th and slc6a3 regions partially overlapping the
fragmentswe tested had also been tested in vivo by other groups (Meng
et al., 2008 and Bai and Burton, 2009, respectively; Fig. 2B) and had also
failed to drive speciﬁc dopaminergic neuron CNS expression.
Fig. 2. (A) Gene order and conserved synteny at ddc, slc6a3, th, and slc18a2 loci between
pufferﬁsh, zebraﬁsh, mouse, and human; scale is approximate (indicated to right).
Zebraﬁsh has partial conservation of syntenywithmammalian orthologs. (B) Schematic
representation of conserved DA motifs in zebraﬁsh dopamine pathway genes (scale is
approximate). DA motifs in tested genomic fragments are represented by red boxes
shown above; enhancer fragments tested are shown below. If signiﬁcant cross-species
conservation (from the UCSC genome site) was present the enhancer fragment is
labeled in green, otherwise the enhancer fragments are shown in blue. Shared (non-
coding) DNA elements between 2 genes are shown as vertical purple lines above the
gene locus; elements shared by 3 genes are shown as green vertical lines; and by all 4
genes as black vertical lines. None of these enhancers was sufﬁcient to drive expression
in dopaminergic neurons in vivo. Also shown are the genomic fragments tested byMeng
et al. (2008) and Bai and Burton (2009), which also failed to recapitulate th and dat
expression, respectively.
Fig. 3. Characterization of Tg(otpb.A:egfp)zc48; confocal images of whole mount embryos doub
Scale bar is 50 μm. (A) Schematic diagram of TH-positive cell groups in the zebraﬁsh brain
immunohistochemistry at 72 hpf in the zebraﬁsh brain. (C) Confocal z-stack projection of GF
different dorsal–ventral levels in the brain of Tg(otpb.A:egfp)zc48 at 72 hpf, showing co-expr
arrowhead points to the NPO neurons. (E–E″) Magniﬁed views of the region boxed in B″, show
(F–F″) Expression at 24 hpf. (G–G″) Expression at 48 hpf.
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conserved regions shared by thedifferent gene loci to look for conserved
DNA motifs. No common shared sequence motifs were identiﬁed in
these highly conserved regions. We conclude that there is not an
obvious single candidate cis-regulatory element that controls expres-
sion in vertebrate dopamine neurons, and that the core regulatory
elements necessary for dopaminergic expression are widely dispersed.
This dispersed pattern of non-coding conservation in the dopa-
mine pathway genes, together with our in vivo testing of speciﬁc
genomic fragments, strongly argues that regulation of the genes
necessary to maintain a dopaminergic phenotype is complex in
vertebrates. In contrast to C. elegans, each group of dopaminergic
neurons in vertebrates may require a distinct combinatorial code to
establish its mature phenotype.Characterization of otpb enhancer
From the enhancer screen (Table 1) we found a genomic DNA
fragment (otpb.A) from the region upstream of the orthopedia-b
(otpb) gene that drove expression in TH-positive neurons of the
diencephalon with minimal expression in other neurons (Fig. 3). otpb
encodes a homeobox transcription factor necessary for dopaminergic
neuron development in zebraﬁsh and in mouse (Del Giacco et al.,
2006; Ryu et al., 2007). Double-labeling for GFP and for TH in the
transgenic line Tg(otpb.A:egfp)zc48 of embryos at 72 hpf showed co-
expression in the diencephalon, primarily in dopaminergic neuron
groups 4 and 6 (based on the nomenclature of Rink and Wullimann,
2002) (Figs. 3E–E″). Expression of GFP in Tg(otpb.A:egfp)zc48 was ﬁrst
visible between 18 and 24 hpf, and became more widespread
between 36 and 48 hpf (Figs. 3F–G″).
TH labels all catecholaminergic neurons, including adrenergic,
noradrenergic, and dopaminergic types. To conﬁrm that the TH-
positive neurons labeled by the otpb.A enhancer were in fact
dopaminergic, we performed double-labeling for the dopamine
transporter (slc6a3) gene. slc6a3 encodes a reuptake transporter of
dopamine that is speciﬁcally expressed in dopaminergic neurons and
not other catecholaminergic neuron types (Nirenberg et al., 1996,
1997; Holzschuh et al., 2001). We used Tg(otpb.A:GAL4)zc57, in which
GAL4-VP16 (Koester and Fraser, 2001) drives expression under the
control of otpb.A (Figs. 4A–A″), to analyze co-expression. Interesting-
ly, when Tg(otpb.A:GAL4)zc57 was crossed to Tg(UAS:GFP), expression
of GFP was found in all TH-positive neurons of the diencephalon, in
contrast to the original Tg(otpb.A:egfp)zc48 line, in which not all diDA
neurons were labeled. This may be due to a position effect of the
original Tg(otpb.A:egfp)zc48 line, or to stronger expression due to
ampliﬁcation by the GAL4/UAS system (Koester and Fraser, 2001). We
observed that diencephalic neurons expressing GFP in the dienceph-
alon also co-expressed slc6a3 (Figs. 4B–B″), conﬁrming that they were
dopaminergic. The otpb.A enhancer also drives expression in the
rostral diencephalon, in the neurosecretory preoptic (NPO) neurons
that require otpb expression for their development (Blechman et al.,
2007). Double-labeling in Tg(otpb.A:GAL4)zc57;Tg(UAS:GFP) embryos
for GFP and for isotocin (the chief neurohypophysial peptide expressed
in the NPO—Unger and Glasgow, 2003) revealed that most of this more
rostral group co-expressed both markers (Figs. 4C–C″). Other neuroen-
docrine-speciﬁc genes are also co-expressed with the otpb.A reporter in
the NPO region (J. Schweitzer, H. Loehr, W. Driever, J.L.B., manuscript in
preparation). These results show that the otpb.A enhancer speciﬁcallyle-labeled for GFP and for TH immunohistochemistry, ventral views, anterior to the top.
at 72 hpf, based on Rink and Wullimann (2002). (B) Confocal z-stack projection of TH
P immunohistochemistry in Tg(otpb.A:egfp)zc48. (D–D″) Confocal z-stack projections at
ession of TH and GFP in diDA neuron groups 4 and 6, but not groups 1 and 2 (arrow);
ing extensive overlap of GFP-positive neurons in the diencephalon with TH expression.
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Fig. 4. Characterization of otpb.A expression in dopaminergic and neuroendocrine cells. Embryos at 72 hpf, Tg(otpb.A:GAL4)zc57, Tg(UAS:GFP). Scale bar is 50 μm. (A–A″) Confocal z-
stack projection of whole-mount embryos double-labeled for GFP and for TH immunohistochemistry, ventral views, anterior to the top. (B) and (C) Plastic horizontal sections of
double-labeled Tg(otpb.A:GAL4)zc57; Tg(UAS:GFP) embryos at 72 hpf, anterior to the top. Higher magniﬁcation inset showing co-localization is indicated by yellow boxed area and is
shown at bottom right of each panel. (B–B″) Labeled for GFP antibody (B) and slc6a3 mRNA (B′), GFP-positive neurons in the diencephalon co-express slc6a3, conﬁrming their
identity as dopaminergic. (C–C″) Labeled for GFP antibody (C) and isotocin mRNA (C′), rostral diencephalon GFP-positive NPO neurons co-express GFP and isotocin.
400 E. Fujimoto et al. / Developmental Biology 352 (2011) 393–404recapitulates otpb gene expression in non-dopaminergic NPO cells and
most if not all diDA neurons.
Regulation of dopaminergic identity and the otpb enhancer
otpb is necessary for development of the diDA neurons and is
expressed in all diDA neurons as well as in the NPO cells (Ryu et al.,
2007; Löhr et al., 2009). In an effort to identify a minimal sufﬁcient
region for diDA expression, we tested multiple genomic fragments in
the otpbgenomic locus, including amore distal genomic region (otpb.D)
(Figs. 5A–C). Some of the fragments failed to drive any CNS expression
(fragments otpb.B, otpb.D, otpb.F, and otpb.H), while some overlapping
fragments drove essentially identical expression in approximately 22–
24 diDA neurons (enhancers otpb.C, otpb.E, and otpb.G) (Fig. 5C). otpb.I
recapitulated only part of the original otpb.A pattern (Figs. 5C andD). To
demonstrate that this partial expressionwas in fact due to an absence of
necessary cis-bindingelements, andnot simply low levels of expression,
we tested the otpb.I fragment (a 444-bp fragment derived from optb.A)
both when driving GFP directly, as well as driving GAL4-VP16
expression in a Tg(UAS:GFP) background. optb.I only drove partial
expression in the NPO and diDA neurons, even when using the GAL4/
UAS:GFP system (Fig. 5D). Thus, otpb.A must contain other importantsequences not included in otpb.I, consistent with our hypothesis that
expression in diDA neurons is regulated by multiple independent cis-
regulatory binding sites spread out over a large genomic region.
Since we had identiﬁed a relatively small region in otpb.A (4.5 kb)
that was sufﬁcient for expression in diDA neurons, we wondered
whether this region containedmotifs that would be sharedwith other
genes expressed in diDA neurons. We performed a comparative
analysis of the otpb.A genomic region (using the sequence obtained
by direct sequencing of the cloned fragment), with the regions
surrounding the ddc, slc6a3, TH, and slc18a2 genes using rVISTA. In
addition, we examined the region upstream of otpa in zebraﬁsh, a
paralog of otpb. We failed to observe any signiﬁcant conservation
(N70%) of sequence from the otpb.A region with otpa, or ddc, slc6a3,
th, or the slc18a2 gene regions. Therefore, the cis-regulatory
sequences, and by extension the transcription factors that bind to
these sequences, are probably different for otpb compared to otpa or
to the dopaminergic phenotype genes.
Discussion
Through a detailed screen for enhancers that drive expression in
CNS dopaminergic neurons, we have identiﬁed a single discrete
Fig. 5. Genomic structure and characterization of otpb genomic locus enhancers. (A) otpb genomic region (not to scale). Coding exons are shown as solid black boxes. DNA fragments
tested for enhancer activity are shown. Region pictured is approximately 20 kb; 3′-most exon of ckmt2 is shown. (B) Screenshot from the UCSC genome browser (http://genome.
ucsc.edu) showing the location of the exons of genes, relative to regions of cross-species conservation (shown as vertical blue lines). Increasing conservation is indicated by
increasing height and/or density of the blue lines. Species used to determine the conservation are shown below. (C) Summary table of expression patterns of the different enhancers
at 72 hpf in the CNS with respect to expression in the diencephalic dopaminergic neurons (diDA) and neurosecretory preoptic nucleus (NPO). (D–D″) Confocal z-stack projection of
whole-mount Tg(otpb.I:GAL4)zc57 embryos at 72 hpf, shown crossed to Tg(UAS:GFP) and double-labeled for GFP (D) and for TH (D′) immunohistochemistry, ventral views, anterior
to the top. Arrows point to the sparse diDA neuron expression.
401E. Fujimoto et al. / Developmental Biology 352 (2011) 393–404enhancer that functions in diencephalic dopaminergic (diDA) neurons
of the zebraﬁsh. This enhancer fragment, otpb.A, drives expression
speciﬁcally in diDA neurons and in NPO neurons of the hypothalamus.
Despite testing a large number of potential enhancers (54 fragments
from 21 genes) with conserved non-coding conservation, most of the
genomic regions we tested failed to have CNS expression in embryos,
with the exception of regions derived from transcription factor genes.
Other groups have also noted previously that genomic regions derived
from locations near transcription factors are more likely to act as
enhancers (Sandelin et al., 2004; Woolfe et al., 2005).
The reason(s) why certain genomic fragments did not work as
enhancers are uncertain. A fragment might work as a silencer of
expression; it might regulate expression at a non-embryonic stage
(for example, Fujimori, 2009); or it might drive expression at very low
levels, although we have tested fragments from th, slc6a3, and ddc
driving GAL4-VP16 and failed to see expression when injected into
UAS:GFP transgenic embryos (data not shown). Another possibility is
that the endogenous promoter associated with a gene might be
necessary for enhancer-driven expression (Gehrig et al., 2009).
However, for slc6a3 we included its known endogenous promoter in
one of our constructs, and for th, drd2b, Fugu dat, otpa, Fugu otpb, and
slc18a2 we tested large fragments immediately upstream of the
translation start site, which were very likely to encompass the
endogenous promoter. Furthermore, we have tested two alternative
minimal promoters (from c-fos and gata2a), and did not ﬁnd
substantive differences in expression compared to the E1b-basedminimal promoter that we used. We suggest a model in which single
DNA elements in isolation are insufﬁcient to specify dopaminergic
neuron phenotype in vertebrates. This is based on our work
examining the otpb.A enhancer in detail, and our analysis (in vivo
and in silico) of the genomic regions surrounding the dopaminergic
phenotype genes. However, our strategy of using non-coding
conservation as a marker of potential enhancers is of limited use in
cases where the genomic annotation is incomplete. For example, in
zebraﬁsh a second tyrosine hydroxylase paralog has recently been
identiﬁed (th2) (Candy and Collet, 2005; Chen et al., 2009; Filippi
et al., 2010; Yamamoto et al., 2010), but which does not have
signiﬁcant expression until 3–4 dpf. Alternative strategies for identi-
fying enhancers have also recently been described; for example, using
tissue-speciﬁc ChIP-seq to identify p300 binding sites (Visel et al.,
2009). To test more formally our model that multiple combined DNA
elements regulate dopaminergic expression, ideally we would like to
have a locus-spanning BAC with a recombineered GFP cassette, and
compare it to isolated genomic fragments either alone or in
combination. However, for the slc6a3 locus for example, there is no
available BAC (database searches, JLB, and personal communication,
Sanger Institute, zebraﬁsh sequencing group) (presumably in part
because of its telomeric location).
Our goal of identifying a vertebrate dopaminergic enhancer was
only partially successful, in contrast to work in C. elegans that
identiﬁed a simple “DA motif” that is necessary for terminal selection
of neuron phenotype (Flames and Hobert, 2009). Loss of the DA motif
Fig. 6.Model of dopaminergic neuron phenotype speciﬁcation in vertebrates. Different
groups of dopamine neurons are speciﬁed by different combinations of transcription
factors, specifying both their dopamine phenotype and other aspects of their identity
(such as their synaptic targets).
402 E. Fujimoto et al. / Developmental Biology 352 (2011) 393–404leads to loss of expression in dopaminergic neurons, and ectopic
expression of the transcription factor ast-1 (which binds the DA
motif) is sufﬁcient to induce a dopaminergic phenotype. Flames and
Hobert propose a model in which dopaminergic neurotransmitter
status is regulated by a single terminal selector gene and its
corresponding cis-motif (the “bar code model”—Spitzer, 2009). The
concept of “terminal selector genes” is appealing and several
examples have been demonstrated in C. elegans (Hobert, 2008).
However, the organization of both gene structure and the nervous
system are considerably less complex in C. elegans compared to
vertebrates. Most enhancers in C. elegans are located in the 1–2 kb
immediately 5′ of the translation start (Okkema and Krause, 2005).
The nervous system of C. elegans is considerably simpler than that of
vertebrates. For example, C. elegans hermaphrodites have a total of
eight dopaminergic neurons, with projections only to the nerve ring
and nerve cord (reviewed in Nass and Blakely, 2003). Thus, the
regulation of dopaminergic phenotype in C. elegans matches the
relative simplicity of its dopaminergic circuits.
Using both bioinformatics and in vivo testing, we were unable to
isolate a compact enhancer from the genomic loci of dopaminergic
phenotype genes (th, slc6a3, slc18a2, and ddc). Rather, we found
multiple conserved motifs dispersed across large genomic regions
around these genes. While in some cases we tested these motifs in
vivo and did not detect enhancer activity, we did not test all of these
motifs, nor did we test them in combination. Furthermore, the otpb.A
enhancer, which drives expression in dopaminergic neurons, does not
share any detectable motifs with neighboring genomic regions of
other dopaminergic phenotype genes, and furthermore cannot be
reduced to a compact DNA module that is sufﬁcient for expression in
dopamine neurons. The otpb.I subfragment (444 bp) of otpb.A only
expresses in 3–4 dopamine neurons, compared to 20–30 for the
original otpb.A fragment, and this does not appear to be due to low
levels of expression. Therefore, otpb.I does not have all the necessary
cis-information to regulate expression in dopaminergic neurons. It is
still formally possible that both our in vivo and in silico analyses have
failed to detect a small, conserved cis-motif in the genomic regions of
the dopaminergic phenotype genes or in the otpb.A enhancer.
The otpb.A enhancer drives expression in most of the diencephalic
dopamine neurons in zebraﬁsh, as well as in neuroendocrine cells,
matching otpb's endogenous expression pattern (Del Giacco et al.,
2006; Ryu et al., 2007). Despite extensive efforts, we were unable to
isolate a minimal region of the otpb.A enhancer that was sufﬁcient for
either dopaminergic or neuroendocrine expression alone. Thus,
regulation of the otpb.A enhancer appears to be coordinated across
the entire 4.5 kb region. In silico analysis did not identify sequences
shared with the genomic regions of otpa or of dopaminergic
phenotype genes. The otpb.A enhancer does provide a valuable tool
for investigating zebraﬁsh diencephalic dopamine neuron develop-
ment and function, with the potential for dopamine neuron speciﬁc-
expression by using combinatorial expression approaches (EF, CBC,
and JLB, unpublished data).
We conclude that in vertebrates dopaminergic cell identity
regulation is dispersed over large genomic regions, and that a
complex regulatory system is necessary for expression of a dopami-
nergic phenotype. This is consistent with other studies showing that
vertebrate gene expression can depend upon widely dispersed cis-
elements (Komisarczuk et al., 2009), in “genomic regulatory blocks”
(reviewed in Kikuta et al., 2007). These ﬁndings suggest that
dopaminergic cell identity is regulated by a mosaic of factors that
dictate not only the dopaminergic neurotransmitter phenotype, but
also other elements of neuronal identity such as synaptic targets and
function (Fig. 6). Our ﬁndings support a model in which distinct
groups of dopaminergic neurons use unique solutions to achieve a
dopaminergic phenotype.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.ydbio.2011.01.023.Acknowledgments
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